DE69730966D1 - Morphogenische behandlung des chronischen nierenversagens - Google Patents

Morphogenische behandlung des chronischen nierenversagens

Info

Publication number
DE69730966D1
DE69730966D1 DE69730966T DE69730966T DE69730966D1 DE 69730966 D1 DE69730966 D1 DE 69730966D1 DE 69730966 T DE69730966 T DE 69730966T DE 69730966 T DE69730966 T DE 69730966T DE 69730966 D1 DE69730966 D1 DE 69730966D1
Authority
DE
Germany
Prior art keywords
treatment
chronic kidney
kidney failure
risk
morphogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730966T
Other languages
English (en)
Other versions
DE69730966T2 (de
Inventor
T Sampath
M Cohen
Slobodan Vukicevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DE69730966D1 publication Critical patent/DE69730966D1/de
Publication of DE69730966T2 publication Critical patent/DE69730966T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69730966T 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens Expired - Lifetime DE69730966T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US643321 1996-05-06
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
PCT/US1997/007816 WO1997041881A1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Publications (2)

Publication Number Publication Date
DE69730966D1 true DE69730966D1 (de) 2004-11-04
DE69730966T2 DE69730966T2 (de) 2006-02-23

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69730966T Expired - Lifetime DE69730966T2 (de) 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens
DE69723845T Expired - Lifetime DE69723845T2 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69723845T Expired - Lifetime DE69723845T2 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens

Country Status (11)

Country Link
US (5) US6498142B1 (de)
EP (2) EP0914146B1 (de)
JP (4) JP4766722B2 (de)
AT (2) ATE245997T1 (de)
AU (2) AU2832297A (de)
CA (2) CA2254953C (de)
DE (2) DE69730966T2 (de)
DK (2) DK0914146T3 (de)
ES (2) ES2203803T3 (de)
PT (2) PT914146E (de)
WO (2) WO1997041880A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU743510B2 (en) * 1997-05-05 2002-01-24 Stryker Corporation Therapies for acute renal failure
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
EP0896825B1 (de) 1997-08-14 2002-07-17 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
CA2336536A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
CA2384948C (en) * 1999-09-14 2013-07-16 Biogen, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
CA2497048A1 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
DK1677735T3 (da) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
GB2430367B (en) 2004-03-30 2009-08-05 Ilypsa Inc Ion binding polymers and uses thereof
US7459527B2 (en) * 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
JP2009515529A (ja) * 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
JP2009524436A (ja) * 2006-01-24 2009-07-02 ノースフィールド ラボラトリーズ、インコーポレイテッド 重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20090197280A1 (en) * 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2047862B9 (de) * 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Mittel zur behandlung von nierenerkrankungen
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
AU2008245900B2 (en) * 2007-04-24 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
CA2725208A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009157165A1 (ja) * 2008-06-24 2009-12-30 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
CN105021826A (zh) * 2008-08-29 2015-11-04 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP3246707B1 (de) * 2008-10-21 2020-09-30 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
US20110207161A1 (en) * 2008-10-21 2011-08-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2742113A1 (en) 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010093941A2 (en) 2009-02-12 2010-08-19 Stryker Corporation COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS
SG2014010680A (en) * 2009-02-12 2014-04-28 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
JP5749659B2 (ja) * 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
EA201290056A1 (ru) 2009-08-07 2012-08-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
AU2010295509A1 (en) 2009-09-17 2012-04-19 Stryker Corporation Buffers for controlling the pH of bone morphogenetic proteins
NZ599773A (en) 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2784889C (en) 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2516456A1 (de) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7-varianten mit reduzierter immunogenität
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
EP3070474A3 (de) 2010-02-26 2016-12-07 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
EP2576587B1 (de) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
EP3339860A1 (de) 2010-06-23 2018-06-27 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
IN2012MN02812A (de) 2010-06-23 2015-05-22 Astute Medical Inc
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
KR101630501B1 (ko) 2010-08-20 2016-06-15 와이어쓰 엘엘씨 디자이너 골형성 단백질
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2013329451B2 (en) 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
PL2946211T3 (pl) 2013-01-17 2018-08-31 Astute Medical, Inc. Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia oraz niewydolności nerek
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
JP2016536588A (ja) * 2013-11-11 2016-11-24 ゼネラル・エレクトリック・カンパニイ ロータ速度の測定における誤差を低減する方法
EP2944326B1 (de) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanin-cyclodextrin-konjugate und deren verwendung zur diagnose von nierenkrankheiten
AU2016218977C1 (en) 2015-02-13 2023-03-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ATE162223T1 (de) 1989-03-28 1998-01-15 Genetics Inst Osteoinduktive zusammensetzungen
DE69132823T2 (de) 1990-05-16 2002-07-18 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
CA2085584C (en) * 1990-06-22 2003-02-11 David John Carini Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6194376B1 (en) 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
JP3627985B2 (ja) 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0825442A3 (de) 1991-08-30 2004-02-11 Curis, Inc. Screeningverfahren von morphogenischen Proteinen
JP3693338B2 (ja) 1991-08-30 2005-09-07 キュリス インコーポレイテッド 組織形成因子誘導による炎症反応の調節
JP4235689B2 (ja) 1991-08-30 2009-03-11 ストライカー・コーポレーション 骨疾患を処置するための骨形成タンパク質
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
DK0653942T3 (da) 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
AU678380B2 (en) 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof
ES2118253T3 (es) 1992-07-31 1998-09-16 Creative Biomolecules Inc Composicion dietetica enriquecida con morfogen.
EP0661987B1 (de) 1992-09-16 1998-01-14 Creative Biomolecules, Inc. Morphogeninduzierte regenerierung der leber
AU681362B2 (en) 1992-11-03 1997-08-28 Stryker Corporation OP-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
CA2157387C (en) 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
EP1364655B1 (de) 1996-03-22 2010-12-29 Stryker Corporation Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
WO1997041881A1 (en) 1997-11-13
US20050143304A1 (en) 2005-06-30
CA2254953C (en) 2006-09-26
WO1997041880A1 (en) 1997-11-13
DK0914146T3 (da) 2005-01-31
DK0910400T3 (da) 2003-11-24
ES2203803T3 (es) 2004-04-16
CA2254954A1 (en) 1997-11-13
EP0910400B1 (de) 2003-07-30
ATE245997T1 (de) 2003-08-15
US8377878B2 (en) 2013-02-19
DE69730966T2 (de) 2006-02-23
CA2254953A1 (en) 1997-11-13
ATE277629T1 (de) 2004-10-15
US20120004171A1 (en) 2012-01-05
PT910400E (pt) 2003-12-31
DE69723845D1 (de) 2003-09-04
US7524817B2 (en) 2009-04-28
JP2012229268A (ja) 2012-11-22
US6498142B1 (en) 2002-12-24
JP4766722B2 (ja) 2011-09-07
JP2000510124A (ja) 2000-08-08
JP2000510835A (ja) 2000-08-22
AU2933997A (en) 1997-11-26
ES2230604T3 (es) 2005-05-01
JP5247593B2 (ja) 2013-07-24
US20100291170A1 (en) 2010-11-18
US8017580B2 (en) 2011-09-13
US6861404B1 (en) 2005-03-01
PT914146E (pt) 2005-02-28
EP0910400A1 (de) 1999-04-28
CA2254954C (en) 2010-01-12
EP0914146B1 (de) 2004-09-29
AU2832297A (en) 1997-11-26
DE69723845T2 (de) 2004-06-03
EP0914146A1 (de) 1999-05-12
JP2009185076A (ja) 2009-08-20

Similar Documents

Publication Publication Date Title
ATE277629T1 (de) Morphogenische behandlung des chronischen nierenversagens
ATE278414T1 (de) Therapien zur behandlung von akutem nierenversagen
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ID18729A (id) Sistem penggantian gigi, komponen-komponen untuk sistem penggantian gigi, dan metoda untuk penggantian gigi tersebut
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
DE69432582D1 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
MXPA02006679A (es) Composicion farmaceutica.
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE226442T1 (de) Anti-chlamydia verfahren und mittel
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
HK1055255A1 (en) Implant comprising immunologically isolated stromal cells and its use
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
DK0972520T3 (da) Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE29716635U1 (de) Distraktionsvorrichtung zur Behandlung von Knochendefekten
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE222479T1 (de) Einheit zur knorpelreparatur
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
DK0834316T3 (da) Anvendelse af sulbutiamin til behandling af psykomotoriske eller psykointellektuelle problemer
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZOO, MICH., US